Dr. Dinh completed a dual doctoral program at the University of Washington in pharmacy and medicinal chemistry. As a graduate student, Dr. Dinh studied how point mutations in Cytochrome P450 2B6 could lead to alterations in drug metabolism of cyclophosphamide and methadone. She then went on to complete a T32 Pediatric Clinical Pharmacology Fellowship at Children’s Mercy Hospital. Here, Dr. Dinh has focused on completing the studies and experiments that serve as the foundation for a decision support tool for atomoxetine and conducting and leading clinical studies that enrolled children with attention deficit/hyperactivity disorder (ADHD).